DDX3X: structure, physiologic functions and cancer

DDX3X is a member of the DEAD-box helicase family, which plays a central role in eukaryotic RNA metabolism. Located on the X chromosome, this protein is ubiquitously expressed and involved in nearly all stages of RNA processing, including transcription, splicing, nuclear export, and translation. Beyond its housekeeping functions, DDX3X is a critical regulator of cellular stress responses, innate immunity, and embryonic development.

DDX3X consists of a highly conserved helicase core flanked by N- and C-terminal regions. The helicase core contains motifs responsible for ATP binding, hydrolysis, and RNA unwinding. The N-terminus contains a nuclear export signal (NES), while the C-terminus features an arginine/serine-rich (RS-like) region that mediates interactions with export receptors. This structural modularity allows DDX3X to act as a scaffold, interacting with numerous proteins such as eIF4E, CRM1, and various transcription factors to modulate gene expression and protein synthesis.

DDX3X has emerged as a significant molecule in cancer research, though its role is notoriously controversial. In some cancers, such as glioma and medulloblastoma, it functions as an oncogene, promoting cell proliferation and metastasis. In others, such as certain types of hepatocellular carcinoma or squamous cell carcinoma, it acts as a tumor suppressor. This dual nature is often dictated by the protein's interaction with key signaling pathways like WNT/β-catenin, P53, and KRAS, as well as its subcellular localization and the specific mutation profile of the tumor.

Because DDX3X is involved in critical pathways that govern cell survival and death, it is a potential therapeutic target. Its ability to regulate translation—specifically the translation of mRNAs containing structured 5′UTRs or upstream open reading frames—makes it a key player in the metastatic potential of cancer cells. Understanding the specific mechanisms by which DDX3X is dysregulated in different tissues is essential for developing targeted therapies that can either inhibit its oncogenic activity or restore its tumor-suppressive functions.